AzTrials
AzTrials

Surgical Remove of HemorrhoidsPhase 4NCT02046772

Safety and Efficacy of the Addition of Morphine Chloride to a Low Dose of Bupivacaine as Intradural Anaesthetic for the Removal Surgery of the Hemorrhoids

A Phase 4 study testing Bupivacaine low dose, Bupivacaine standard dose and Morphine Chloride in people with Surgical Remove of Hemorrhoids, run by Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias at 2 sites in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A single blind, randomized, with blinded evaluation by third parties clinical trial is carried out to assess the analgesic efficay of the addition of morphine chloride to a low dose solution of spinal local anaesthetic compared to a standard dose spinal anaesthetic in the haemorrhoid surgery. Read more about this study

Who is it for?
Ages 18 to 64 years
Conditions the study is for
Surgical Remove of Hemorrhoids
What is being tested?
Bupivacaine low dose, Bupivacaine standard dose and Morphine Chloride
Could I receive a placebo?
No, everyone receives an active treatment
How many people
63 participants
Where
2 sitesSpain
Study dates
Mar 2012to Mar 2014
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 64 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patients undergoing hemorrhoidectomy.
  • Age between 18 and 64.
  • Both gender
  • ASA I to III.
  • With indication for spinal block.
  • People capable to grant the informed consent.

Who cannot join

  • Patients with allergies to the study drugs.
  • Patients with any contraindication for performing a spinal technique (coagulation disorders, fever, intracraneal hypertension, abscess in the puncture site, etc..).
  • Patients with previous neurological disorders.
  • Pregnant women.
  • Women who may be pregnant and do not have a negative pregnancy test.
  • Breastfeeding women.
  • Patients with uncapable to give informed consent.

Trial locations and contacts

2 sites in 1 country.

Spain2 sites
  • Hospital Universitario Principe de Asturias

    Alcalá de Henares, Madrid, 28805

  • Hospital del Henares

    Coslada, Madrid, 28822

Other trials in Spain

About this study

Official title: Assessment of the Analgesic Efficacy of Morphine Chloride in Addition to a Low Dose Solution of Spinal Anaesthetic in Hemorrhoidectomy Compared to a Standard Dose of Spinal Local Anaesthetic. Simple Blind, Randomized, With Blinded Evaluation by Third Parties Clinical Trial.

A single blind, randomized, with blinded evaluation by third parties clinical trial is carried out to assess the analgesic efficay of the addition of morphine chloride to a low dose solution of spinal local anaesthetic compared to a standard dose spinal anaesthetic in the haemorrhoid surgery.

The objective of this clinical trial is to assess if the experimental treatment is as efficacy as the standard treatment in the anesthetic and analgesic effects with less side effects, greater and earlier mobility after surgery and shortened the hospitalization.

Read the detailed description

DESIGN OF THE TRIAL:

A multicentre, randomized, single-blind, with masked evaluationby third parties clinical trial.

The Clinical Pharmacology Unit will perform a permuted blocks randomization scheme for each of the two hospitals participating in the trial. The result of this randomization will be kept in this unit and will not be accessible to investigators. Investigators will receive a series of opaque sealed envelopes with a number corresponding to the order of entry of the patients into the trial. When the patient is in the operating room, investigators must open the envelope which contains the group of treatment assigned to that patient. The patient will not know in which intervention group is included. Investigator who performs the spinal puncture and investigator who collects the data and performs the evaluation will no be the same person. This will allow a blind evaluation.

OBJECTIVES:

Main objective:

To evaluate whether the addition of morphine chloride to a low dose solution of local intradural anaesthetic in patients undergoing hemorrhoids surgery produces an anaesthetic efficacy comparable to that produced by a standard dose of local intradural anaesthetic and an improvement of postoperative analgesic efficacy.

Secondary objectives:

  • Earlier mobilization of the patient.
  • Minor adverse effects.
  • A shorter hospital stay of the patient.

TREATMENTS:

Two groups of treatment will be formed, experimental and comparator. The experimental group will receive 3mg of Bupivacaine with addition of 50 micrograms of Morphine Chloride.

The comparator group will receive 5 mg of Bupivacaine.

RESCUE TREATMENTS

If necessary before surgery, midazolam will be administered from 0.02 to 0.05 mg / kg intravenous (IV) depending on clinical response and after the patient is set in the surgical position, if necessary, an intravenous infusion of propofol will be administered at 0.5 - 2mg / kg / h. Sedative drugs with analgesic effects as opioids, ketamine, etc, will be avoided to not interfere with the main analgesic study assessment.

After surgery and during the hospitalization stay the rescue analgesia treatment will be administered only on demand. The rescue treatment allowed by protocol will be an intravenous administration of dexketoprofen up to 50 mg / 8 h and if insufficient, a rescue of 3 mg of morphine chloride will be administered. If morphine chloride is received, these patients will be recorded in the case report forms as inefficacy of the treatment. At home, after discharge, patients will receive rescue analgesia with capsules of dexketoprofen 25 mg / 8 h. (up to 75 mg a day).

SAMPLE SIZE:

66 patients ( 33 patients in the experimental group and 33 patients in the control group)

EFFICACY ASSESSMENT

Pain will be assessed using a visual analog scale (VAS from 0 to 10) at the beginning and end of surgery, at the arrival of resuscitation unit, after 10 and 30 minutes after arrival, during hospitalization stay out of the resuscitation unit and daily at home after discharge.

Doses required of rescue analgesia and hospitalization time will be recorded.

SAFETY ASSESSMENT

Basic monitoring as usual will be perfomed in the surgery room. Motor blockage will be assessed using the modified Bromage scale as follows: 1 = complete motor blocking, 2 = able to move feet only, 3 = patient move the feet and bend the knee, 4 = straight leg raises <30 ° or > 30 ° but not against resistance, 5 = lifts leg> 30 ° against resistance. This measure will be made after surgery in the surgery room and at the arrival and at one hour after resuscitation unit admission.

All the Adverse events will be reported.

Being tested
Bupivacaine low dose, Bupivacaine standard dose, Morphine Chloride
Keywords
hemorrhoidectomy, analgesia, anaesthetic, bupivacaine, morphine chloride
Medical subject headings
Agnosia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bupivacaine low doseDrug

    A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural

  • Bupivacaine standard doseDrug

    Single intradural standard dose of bupivacaine

  • Morphine ChlorideDrug

    A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural

Study groups in NCT02046772
Study groupRoleWhat they receive
Bupivacaine + Morphine ChlorideExperimentalPeople in this arm will receive treatment with morphine chloride in addition to a low dose solution of the local intradural anaesthetic bupivacaine.
Receives: Drug: Bupivacaine low dose; Drug: Morphine Chloride
Bupivacaine standard doseActive comparatorPeople in this arm will receive treatment with the standard dose of the local intradural anaesthetic bupivacaine
Receives: Drug: Bupivacaine standard dose

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measurement of Time to Start the Anaesthetic Effect

    To compare whether the addition of morphine chloride to a low dose intradural solution of the local anaesthetic bupivacaine is as effective as an administration of a single dose of bupivacaine.

    Measured: First 20 minutes between administration and beginning of surgery

  2. Measurement of the Analgesic Effect After Surgery by VAS From 0 to 10, Where 0 is no Pain and 10 is the Worst Pain Imaginable.

    To compare whether the addition of morphine chloride to a low dose solution of bupivacaine and improves the analgesic treatment than a single administration of bupivacaine.

    Measured: Up to 72 hours from the end of the surgery in the hospital stay and during the next 7 days at home, after discharge

Secondary outcomes (3)
  1. Greater and Earlier Mobilization Measured by Bromage Scale.

    To assess whether the administration of morphine chloride in addition to a low dose solution of local intradural anaesthetic (bupivacaine) improves the mobilization of the patients after surgery more than the single intradural administration of bupivacaine.

    Total Score in the Bromage Scale goes from 1 to 5, where:

    1: complete motor blocking - 2: capable to move the feet - 3: moves the feet and bends the knee - 4: raise the leg straight more or less than 30 degrees but no against resistance - 5: raise the leg straight more than 30 degrees against resistance (no motor blocking)

    Measured: During the first 24 hours after surgery and at the entry and exit of the resuscitation unit

  2. Number of Adverse Events

    To assess if the experimental treatment causes less, equal or more adverse events than the comparator treatment.

    Measured: Up to 72 hours from the intervention and the hopitalary stay and during the next 7 days after discharge

  3. Time of Hospitalization

    To see if the hospitalization time is shortened or not by the experimental treatment.

    Measured: Up to 72 hours after the intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jan 2014 (estimated)
  2. Study startMar 2012
  3. Primary completionMar 2014
  4. Study completionMar 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
63 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02046772
Sponsor's protocol ID
HUPA-EC-01-2012
Other IDs
2012-000110-11
Status last verified
Aug 2014
First submitted
22 Jan 2014
Last updated
15 Aug 2016
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Bupivacaine low dose, Bupivacaine standard dose and Morphine Chloride in people with Surgical Remove of Hemorrhoids, run by Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias at 2 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Aug 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Sep 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measurement of Time to Start the Anaesthetic Effect (time frame: First 20 minutes between administration and beginning of surgery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in